HOUSE_OVERSIGHT_024104.jpg
1.68 MB
Extraction Summary
0
People
29
Organizations
0
Locations
0
Events
2
Relationships
2
Quotes
Document Information
Type:
Financial portfolio report / investment schedule
File Size:
1.68 MB
Summary
This document is a confidential financial schedule detailing the 'Healthcare Technology Portfolio' performance for two funds: Sprout Capital VII, L.P. and Sprout Growth II, L.P., as of March 31, 2014. It lists specific portfolio companies (such as WebMD, Cephalon, and Adeza Biomedical), the vintage year of investment (ranging 1994-2003), investment costs, realized values, and Internal Rates of Return (IRR). The document bears a House Oversight Bates stamp (HOUSE_OVERSIGHT_024104), indicating it was part of a congressional investigation, likely related to financial probes involving entities connected to the broader Epstein investigation.
Organizations (29)
Relationships (2)
Listed as portfolio company with $39.8M realized value
Listed as portfolio company with $20.5M realized value
Full Extracted Text
Complete text extracted from the document (4,072 characters)
Sprout Capital VII, L.P. (Healthcare Technology Portfolio)
$ amounts in millions, as of March 31, 2014
Please refer to Endnotes I,J,K,L,M and N in this Appendix.
$ amounts in millions, as of March 31, 2014
Please refer to Endnotes I,J,K,L,M and N in this Appendix.
[Table Headers]
Company | Sector | Vintage Year | Total Cost | Realized Value | Unrealized Value | Total Value | Gross Multiple (Realized Portion) | Gross Multiple (Total) | Gross IRR
Company | Sector | Vintage Year | Total Cost | Realized Value | Unrealized Value | Total Value | Gross Multiple (Realized Portion) | Gross Multiple (Total) | Gross IRR
All Investments
Adeza Biomedical Corporation | Diagnostics & Infrastructure | 1996 | $ 4.8 | $ 27.7 | $ - | $ 27.7 | 5.75 | 5.75 | 20.1%
Allos Therapeutics, Inc. | Therapeutics | 1998 | $ 2.6 | $ 7.5 | $ - | $ 7.5 | 2.87 | 2.87 | 38.8%
Aradigm Corporation | Therapeutics | 1994 | $ 2.8 | $ 15.3 | $ - | $ 15.3 | 5.45 | 5.45 | 39.3%
AtheroGenics, Inc. | Therapeutics | 1996 | $ 3.8 | $ 7.1 | $ - | $ 7.1 | 1.87 | 1.87 | 13.7%
AviaHealth, Inc. (fka GoToMyDoc) | Convergence | 2000 | $ 1.6 | $ 0.0 | $ - | $ 0.0 | 0.02 | 0.02 | -92.8%
CombiChem, Inc. | Therapeutics | 1995 | $ 3.9 | $ 9.4 | $ - | $ 9.4 | 2.43 | 2.43 | 26.5%
Connetics Corp. (fka Connective) | Therapeutics | 1995 | $ 6.3 | $ 14.2 | $ - | $ 14.2 | 2.24 | 2.24 | 15.5%
FemRX | Healthcare Devices | 1995 | $ 2.2 | $ 3.2 | $ - | $ 3.2 | 1.47 | 1.47 | 11.6%
Healtheon/WebMD (Sapient) | Convergence | 1996 | $ 3.0 | $ 39.8 | $ - | $ 39.8 | 13.42 | 13.42 | 190.1%
Hearten Medical | Healthcare Devices | 1997 | $ 1.7 | $ - | $ - | $ - | - | - | NM
IntraBiotics Pharmaceuticals | Therapeutics | 1994 | $ 3.9 | $ 7.3 | $ - | $ 7.3 | 1.89 | 1.89 | 13.4%
Lynx Therapeutics, Inc. | Diagnostics & Infrastructure | 1995 | $ 1.1 | $ 2.9 | $ - | $ 2.9 | 2.72 | 2.72 | 25.4%
NxStage Medical, Inc. | Healthcare Devices | 2003 | $ 3.3 | $ 18.9 | $ - | $ 18.9 | 5.80 | 5.80 | 20.9%
Orquest, Inc. | Healthcare Devices | 1995 | $ 5.5 | $ 7.8 | $ - | $ 7.8 | 1.42 | 1.42 | 6.1%
Pathology Partners | Diagnostics & Infrastructure | 1997 | $ 3.3 | $ 22.4 | $ - | $ 22.4 | 6.82 | 6.82 | 38.2%
Pharsight Corporation | Convergence | 1997 | $ 4.9 | $ 7.3 | $ - | $ 7.3 | 1.48 | 1.48 | 6.0%
Point Biomedical | Diagnostics & Infrastructure | 1997 | $ 9.2 | $ 0.0 | $ - | $ 0.0 | 0.00 | 0.00 | NM
Prometheus Laboratories, Inc. | Therapeutics | 1998 | $ 7.8 | $ 38.8 | $ - | $ 38.8 | 5.00 | 5.00 | 13.4%
Salient Interventional Systems | Healthcare Devices | 1998 | $ 2.7 | $ 0.0 | $ - | $ 0.0 | 0.00 | 0.00 | NM
Skila, Inc. | Convergence | 1998 | $ 5.2 | $ 0.2 | $ - | $ 0.2 | 0.05 | 0.05 | NM
TriPath Imaging, Inc. | Diagnostics & Infrastructure | 1996 | $ 4.9 | $ 13.9 | $ - | $ 13.9 | 2.83 | 2.83 | 17.2%
VascA, Inc. | Healthcare Devices | 1996 | $ 6.5 | $ 0.1 | $ - | $ 0.1 | 0.02 | 0.02 | NM
VNUS Medical Technologies, Inc. | Healthcare Devices | 1997 | $ 4.3 | $ 15.7 | $ - | $ 15.7 | 3.66 | 3.66 | 12.1%
Xcyte Therapies, Inc. (CDR) | Therapeutics | 1996 | $ 6.1 | $ 0.5 | $ - | $ 0.5 | 0.08 | 0.08 | -33.6%
Adeza Biomedical Corporation | Diagnostics & Infrastructure | 1996 | $ 4.8 | $ 27.7 | $ - | $ 27.7 | 5.75 | 5.75 | 20.1%
Allos Therapeutics, Inc. | Therapeutics | 1998 | $ 2.6 | $ 7.5 | $ - | $ 7.5 | 2.87 | 2.87 | 38.8%
Aradigm Corporation | Therapeutics | 1994 | $ 2.8 | $ 15.3 | $ - | $ 15.3 | 5.45 | 5.45 | 39.3%
AtheroGenics, Inc. | Therapeutics | 1996 | $ 3.8 | $ 7.1 | $ - | $ 7.1 | 1.87 | 1.87 | 13.7%
AviaHealth, Inc. (fka GoToMyDoc) | Convergence | 2000 | $ 1.6 | $ 0.0 | $ - | $ 0.0 | 0.02 | 0.02 | -92.8%
CombiChem, Inc. | Therapeutics | 1995 | $ 3.9 | $ 9.4 | $ - | $ 9.4 | 2.43 | 2.43 | 26.5%
Connetics Corp. (fka Connective) | Therapeutics | 1995 | $ 6.3 | $ 14.2 | $ - | $ 14.2 | 2.24 | 2.24 | 15.5%
FemRX | Healthcare Devices | 1995 | $ 2.2 | $ 3.2 | $ - | $ 3.2 | 1.47 | 1.47 | 11.6%
Healtheon/WebMD (Sapient) | Convergence | 1996 | $ 3.0 | $ 39.8 | $ - | $ 39.8 | 13.42 | 13.42 | 190.1%
Hearten Medical | Healthcare Devices | 1997 | $ 1.7 | $ - | $ - | $ - | - | - | NM
IntraBiotics Pharmaceuticals | Therapeutics | 1994 | $ 3.9 | $ 7.3 | $ - | $ 7.3 | 1.89 | 1.89 | 13.4%
Lynx Therapeutics, Inc. | Diagnostics & Infrastructure | 1995 | $ 1.1 | $ 2.9 | $ - | $ 2.9 | 2.72 | 2.72 | 25.4%
NxStage Medical, Inc. | Healthcare Devices | 2003 | $ 3.3 | $ 18.9 | $ - | $ 18.9 | 5.80 | 5.80 | 20.9%
Orquest, Inc. | Healthcare Devices | 1995 | $ 5.5 | $ 7.8 | $ - | $ 7.8 | 1.42 | 1.42 | 6.1%
Pathology Partners | Diagnostics & Infrastructure | 1997 | $ 3.3 | $ 22.4 | $ - | $ 22.4 | 6.82 | 6.82 | 38.2%
Pharsight Corporation | Convergence | 1997 | $ 4.9 | $ 7.3 | $ - | $ 7.3 | 1.48 | 1.48 | 6.0%
Point Biomedical | Diagnostics & Infrastructure | 1997 | $ 9.2 | $ 0.0 | $ - | $ 0.0 | 0.00 | 0.00 | NM
Prometheus Laboratories, Inc. | Therapeutics | 1998 | $ 7.8 | $ 38.8 | $ - | $ 38.8 | 5.00 | 5.00 | 13.4%
Salient Interventional Systems | Healthcare Devices | 1998 | $ 2.7 | $ 0.0 | $ - | $ 0.0 | 0.00 | 0.00 | NM
Skila, Inc. | Convergence | 1998 | $ 5.2 | $ 0.2 | $ - | $ 0.2 | 0.05 | 0.05 | NM
TriPath Imaging, Inc. | Diagnostics & Infrastructure | 1996 | $ 4.9 | $ 13.9 | $ - | $ 13.9 | 2.83 | 2.83 | 17.2%
VascA, Inc. | Healthcare Devices | 1996 | $ 6.5 | $ 0.1 | $ - | $ 0.1 | 0.02 | 0.02 | NM
VNUS Medical Technologies, Inc. | Healthcare Devices | 1997 | $ 4.3 | $ 15.7 | $ - | $ 15.7 | 3.66 | 3.66 | 12.1%
Xcyte Therapies, Inc. (CDR) | Therapeutics | 1996 | $ 6.1 | $ 0.5 | $ - | $ 0.5 | 0.08 | 0.08 | -33.6%
Total Sprout Capital VII, L.P. (HCT) Investments | | | $ 101.2 | $ 260.0 | $ - | $ 260.0 | 2.57 | 2.57 | 18.6%
Sprout Growth II, L.P. (Healthcare Technology Portfolio)
$ amounts in millions, as of March 31, 2014
Please refer to Endnotes I,J,K,L,M and N in this Appendix.
$ amounts in millions, as of March 31, 2014
Please refer to Endnotes I,J,K,L,M and N in this Appendix.
[Table Headers]
Company | Sector | Vintage Year | Total Cost | Realized Value | Unrealized Value | Total Value | Gross Multiple (Realized Portion) | Gross Multiple (Total) | Gross IRR
Company | Sector | Vintage Year | Total Cost | Realized Value | Unrealized Value | Total Value | Gross Multiple (Realized Portion) | Gross Multiple (Total) | Gross IRR
All Investments
Adeza Biomedical Corporation | Diagnostics & Infrastructure | 1996 | $ 3.9 | $ 22.7 | $ - | $ 22.7 | 5.75 | 5.75 | 20.1%
AviaHealth, Inc. (fka GoToMyDoc) | Convergence | 2000 | $ 1.3 | $ 0.0 | $ - | $ 0.0 | 0.02 | 0.02 | -92.8%
Cephalon, Inc. | Therapeutics | 1999 | $ 4.1 | $ 20.5 | $ - | $ 20.5 | 5.01 | 5.01 | 293.2%
Connetics Corp. (fka Connective) | Therapeutics | 1997 | $ 3.2 | $ 6.5 | $ - | $ 6.5 | 2.05 | 2.05 | 16.7%
IVAC Holdings, Inc. | Healthcare Devices | 1995 | $ 0.9 | $ 3.0 | $ - | $ 3.0 | 3.31 | 3.31 | 121.9%
Pathology Partners | Diagnostics & Infrastructure | 1997 | $ 2.7 | $ 18.3 | $ - | $ 18.3 | 6.82 | 6.82 | 38.1%
Adeza Biomedical Corporation | Diagnostics & Infrastructure | 1996 | $ 3.9 | $ 22.7 | $ - | $ 22.7 | 5.75 | 5.75 | 20.1%
AviaHealth, Inc. (fka GoToMyDoc) | Convergence | 2000 | $ 1.3 | $ 0.0 | $ - | $ 0.0 | 0.02 | 0.02 | -92.8%
Cephalon, Inc. | Therapeutics | 1999 | $ 4.1 | $ 20.5 | $ - | $ 20.5 | 5.01 | 5.01 | 293.2%
Connetics Corp. (fka Connective) | Therapeutics | 1997 | $ 3.2 | $ 6.5 | $ - | $ 6.5 | 2.05 | 2.05 | 16.7%
IVAC Holdings, Inc. | Healthcare Devices | 1995 | $ 0.9 | $ 3.0 | $ - | $ 3.0 | 3.31 | 3.31 | 121.9%
Pathology Partners | Diagnostics & Infrastructure | 1997 | $ 2.7 | $ 18.3 | $ - | $ 18.3 | 6.82 | 6.82 | 38.1%
Total Sprout Growth II, L.P. (HCT) Investments | | | $ 16.1 | $ 70.9 | $ - | $ 70.9 | 4.42 | 4.42 | 43.8%
93
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024104
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024104
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document